PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
figure26_large.png
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial - The Lancet
Unmet Needs in the Secondary Prevention in ACS: The Dual Pathway Approach (Transcript)
Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome – Thrombolysis in Myocardial Infarction. - ppt download
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
Thrombin and Myocardial Infarction: Implications for Oral Anticoagulation (Transcript)
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
ATLAS - Rivaroxaban in patients with a recent ACS — NERDCAT
ATLAS ACS 2-TIMI 51: Efficacy Endpoints: Very Low-Dose 2.5 mg BID - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet - wikidoc
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
Factor Xa Inhibitors in Coronary Artery Disease - ppt download
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
PPT - C. Michael Gibson, MS, MD on behalf of the ATLAS ACS 2 TIMI 51 Investigators PowerPoint Presentation - ID:1519803
The ATLAS ACS 2-TIMI 51 trial [11] | Download Table
Dia 1
NOACS: Emerging data in ACS/IHD - ppt download
ATLAS ACS 2-TIMI 51: Statistical Analysis Pre-specified Primary Efficacy Analysis - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?